Sai Parenterals Q2 FY27: revenue ₹195 Cr, net profit ₹11 Cr
Results · Finvezto · 2 Nov 2026 · Sai Parenterals (SAIPARENT)
Results Q2 FY27, ₹ Cr
| Q2 FY27 | ₹ Cr | QoQ | YoY |
|---|---|---|---|
| Revenue | 195 | - | - |
| Operating profit | 40 | - | - |
| Net profit | 11 | - | - |
| Operating margin | 20.6% | - | - |
| Net margin | 5.4% | - | - |
YoY is the company's own figure. QoQ shows where our quarterly series matches the filing.
Key points
- Consolidated revenue from operations rose 9% sequentially to INR 196.1 crores in Q2 FY27, while H1 FY27 revenue reached INR 376.0 crores. Earnings call
- Gross margin improved to 47.5% and EBITDA margin expanded to 21.1% in Q2 FY27, driven by tighter inventory management and lower raw material costs. Earnings call
- The company completed acquisitions for a 60% stake in Saicriti Pharma and a 60% stake in Sai Prathyak Laboratories using IPO proceeds. Earnings call
What to watch
- Management on adelaide facility timeline: And we expect the facility to be commissioned in January of 2027, slightly behind where we previously advised, and this delay has been caused by logistics disruptions due to the Iran conflict.
- Management on saicriti injectable facility timeline: This new injectable facility on track for July 2027.
Links
Company page · Results tracker
Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630.